JP2017521367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521367A5 JP2017521367A5 JP2016568912A JP2016568912A JP2017521367A5 JP 2017521367 A5 JP2017521367 A5 JP 2017521367A5 JP 2016568912 A JP2016568912 A JP 2016568912A JP 2016568912 A JP2016568912 A JP 2016568912A JP 2017521367 A5 JP2017521367 A5 JP 2017521367A5
- Authority
- JP
- Japan
- Prior art keywords
- halo
- disorder
- less
- fluoro
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- -1 Heteroalkynyl Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000004031 partial agonist Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000009977 dual effect Effects 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000001914 Fragile X syndrome Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002346 iodo group Chemical group I* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010010144 Completed suicide Diseases 0.000 claims 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 claims 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 claims 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 claims 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 claims 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 claims 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 claims 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 claims 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000037870 generalized anxiety Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000286P | 2014-05-19 | 2014-05-19 | |
| US62/000,286 | 2014-05-19 | ||
| PCT/US2015/031523 WO2015179366A1 (en) | 2014-05-19 | 2015-05-19 | Serotonin receptor-targeting compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521367A JP2017521367A (ja) | 2017-08-03 |
| JP2017521367A5 true JP2017521367A5 (enExample) | 2018-06-28 |
| JP6817073B2 JP6817073B2 (ja) | 2021-01-20 |
Family
ID=54554616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568912A Active JP6817073B2 (ja) | 2014-05-19 | 2015-05-19 | セロトニン受容体を標的にする化合物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11021435B2 (enExample) |
| EP (1) | EP3145906B1 (enExample) |
| JP (1) | JP6817073B2 (enExample) |
| CN (1) | CN106573872B (enExample) |
| BR (1) | BR112016027096B1 (enExample) |
| ES (1) | ES2967976T3 (enExample) |
| WO (1) | WO2015179366A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3297979B1 (en) * | 2015-05-19 | 2024-11-20 | Northeastern University | Compounds and methods for modulating serotonin receptors in the periphery |
| CN108794308B (zh) * | 2017-04-27 | 2021-07-20 | 北京大学深圳研究生院 | 1,2,3,4-四氢萘类化合物及其制备方法和应用 |
| KR20220122602A (ko) * | 2019-10-23 | 2022-09-02 | 맵라이트 세라퓨틱스, 인크. | 자폐 스펙트럼 장애의 증상을 치료하는 방법 |
| KR20230073197A (ko) * | 2020-08-19 | 2023-05-25 | 노스이스턴 유니버시티 | 세로토닌 수용체 조절제 |
| CN117730073A (zh) * | 2021-07-14 | 2024-03-19 | 东北大学 | 血清素5-ht2a、5-ht2b和5-ht2c受体反向激动剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| GB9509156D0 (en) * | 1995-05-05 | 1995-06-28 | Sandoz Ltd | Organic compounds |
| ES2219679T3 (es) | 1995-10-18 | 2004-12-01 | Akzo Nobel N.V. | Vacuna de combinacion contra la enfermedad de newcastle. |
| US20030008880A1 (en) * | 2001-05-02 | 2003-01-09 | Pfizer Inc. | 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity |
| EP1956006A1 (en) * | 2007-02-06 | 2008-08-13 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands |
| EP1975161A1 (en) * | 2007-03-28 | 2008-10-01 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments |
| WO2008154044A1 (en) * | 2007-06-15 | 2008-12-18 | University Of Florida Research Foundation | Therapeutic compounds and methods of use |
| US8586634B2 (en) | 2007-06-15 | 2013-11-19 | University Of Florida Research Foundation, Inc. | Therapeutic compounds |
| WO2009061436A1 (en) * | 2007-11-06 | 2009-05-14 | University Of Florida Research Foundation | Compound for activating 5-ht2c receptors in combination with an amphetamine compound |
| US9024071B2 (en) * | 2009-05-05 | 2015-05-05 | University Of Florida Research Foundation, Inc. | Therapeutic compounds |
-
2015
- 2015-05-19 US US15/311,905 patent/US11021435B2/en active Active
- 2015-05-19 CN CN201580039372.8A patent/CN106573872B/zh active Active
- 2015-05-19 WO PCT/US2015/031523 patent/WO2015179366A1/en not_active Ceased
- 2015-05-19 EP EP15796940.3A patent/EP3145906B1/en active Active
- 2015-05-19 ES ES15796940T patent/ES2967976T3/es active Active
- 2015-05-19 BR BR112016027096-7A patent/BR112016027096B1/pt active IP Right Grant
- 2015-05-19 JP JP2016568912A patent/JP6817073B2/ja active Active